A network meta-Analysis on comparative efficacy and all-cause discontinuation of antimanic treatments in acute bipolar mania

Psychological Medicine

Volumn 45, Issue 2, 2015, Pages 299-317

  Yildiz, A ^a,b   Nikodem, M ^c   Vieta, E ^b,d   Correll, C U ^e   Baldessarini, R J ^f  

^a Depression and Bipolar Disorders Foundation Duygudurum Vakfi DUVAK   (Turkey)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

^c AGH UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Poland)

^d UNIVERSITY OF BARCELONA   (Spain)

^e ZUCKER HILLSIDE HOSPITAL   (United States)

^f HARVARD MEDICAL SCHOOL   (United States)

Author keywords

All cause discontinuations; antimanic; bipolar; mania; multiple treatments meta Analysis

Indexed keywords

TRANQUILIZER;

BAYES THEOREM; BIPOLAR DISORDER; CLASSIFICATION; HUMAN; META ANALYSIS; PATIENT DROPOUTS; RANDOMIZED CONTROLLED TRIAL (TOPIC); STATISTICS AND NUMERICAL DATA; TREATMENT OUTCOME;

ANTIMANIC AGENTS; BAYES THEOREM; BIPOLAR DISORDER; HUMANS; PATIENT DROPOUTS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT OUTCOME;

EID: 84927690413     PISSN: 00332917     EISSN: 14698978     Source Type: Journal    
DOI: 10.1017/S0033291714001305     Document Type: Article

References (75)

1. Ades AE, Sculpher M, Sutton A, Abrams K, Cooper N, Welton N, Lu G (2006). Bayesian methods for eviDence aynthesis in cost-effectiveness analysis. Pharmacoeconomics 24, 1-19
2. Ades AE, Welton N, Lu G. Introduction to Mixed Treatment Comparisons. (https://www.bris.ac.uk/cobm/research/mpes/mtc.html). Accessed 20 January 2014
3. Ahrens B, Müller-Oerlinghausen B, Schou M, Wolf T, Alda M, Grof E, Grof P, Lenz G, Simhandl C, Thau K, Volk J, Wolf R, Wolf T (1995). Excess cardiovascular and suicide mortality of affective disorDers may be reduced by lithium prophylaxis. Journal of Affective DisorDers 33, 67-75
4. Altman DG (1998). ConfiDence intervals for the number needed to treat. British Medical Journal 317, 1309-1312
5. American Psychiatric Association (2000). Diagnostic and Statistical Manual of Mental DisorDers, 4th edn. text revision. APA: Washington, DC
6. Bachmann RF, Wang Y, Yuan P, Zhou R, Li X, Alesci S, Du J, Manji HK (2009). Common effects of lithium and valproate on mitochondrial functions: protection against methamphetamine-induced mitochondrial damage. International Journal of Neuropsychopharmacology 12, 805-822
7. Baldessarini RJ (2013). Chemotherapy in Psychiatry, 3rd edn. Springer Press: New York, NY
8. Beigel A, Murphy DL (1971). Assessing clinical characteristics of the manic state. American Journal of Psychiatry 128, 688-694
9. Bose A, Starace A, Wang Q, Diaz E, Goodman J, Ruth A, Nmeth G, Laszlovszky I (2012). Cariprazine in the treatment of acute mania in bipolar disorDer: a double-blind, placebo-controlled, phase trial. ClinicalTrials.gov: NCT01058096. European Neuropsychopharmacology 22 (Suppl. 2), S285
10. BowDen CL, Göʇüş A, Grunze H, Hggström L, Rybakowski J, Vieta E (2008). 12-week, open, randomized trial comparing sodium valproate to lithium in patients with bipolar I disorDer suffering from a manic episode. International Journal of Clinical Psychopharmacology 23, 254-262
11. BowDen CL, Mosolov S, Hranov L, Chen E, Habil H, Kongsakon R, Manfredi R, Lin HN (2010). Efficacy of valproate vs. lithium in mania or mixed mania: randomized, open 12-week trial. International Journal of Clinical Psychopharmacology 25, 60-67
12. Brown D, Silverstone T, Cookson J (1989). Carbamazepine compared to haloperidol in acute mania. International Journal of Clinical Psychopharmacology 4, 229-238
13. Calabrese JR, Keck PE Jr., Starace A, Lu K, Ruth A, Laszlovszky I, Nemeth G, Durgam S (2013). Efficacy and safety of low-And high-dose cariprazine in patients with acute mania associated with bipolar I disorDer. ClinicalTrials.gov: NCT01058668. European Neuropsychopharmacology 23 (Suppl. 2), S378-S379
14. Caldwell DM, Ades AE, Higgins JP (2005). Simultaneous comparison of multiple treatments: combining direct and indirect eviDence. British Medical Journal 331, 897-900
15. Centorrino F, Masters GA, Talamo A, Baldessarini RJ, Ongür D (2012). Metabolic syndrome in psychiatrically hospitalized patients treated with antipsychotics and other psychotropics. Human Psychopharmacology 27, 521-526
16. Chaimani C, Salanti G (2012). Using network meta-Analysis to evaluate the existence of small-study effects in a network of interventions. Research Synthesis Methods 3, 161-176
17. Chang CK, Hayes RD, Perera G, Broadbent MT, Fernandes AC, Lee WE, Hotopf M, Stewart R (2011). Life expectancy at birth for people with serious mental illness and other major disorDers from a secondary mental health care case register in London. PLoS ONE 6, e19590
18. Chinn S (2000). Simple method for converting an odds ratio to effect size for use in meta-Analysis. Statistics in Medicine 19, 3127-3131
19. Cipriani A, Barbui C, Salanti G, Rendell J, Brown R, Stockton S, Purgato M, Spineli LM, Goodwin GM, Geddes JR (2011). Comparative efficacy and acceptability of antimanic drugs in acute mania: multiple-treatments meta-Analysis. Lancet 378, 1306-1315
20. Cipriani A, Furukawa TA, Salanti G, Geddes JR, Higgins JP, Churchill R, Watanabe N, Nakagawa A, Omori IM, McGuire H, Tansella M, Barbui C (2009). Comparative efficacy and acceptability of 12 new-generation antidepressants: a multiple-treatments meta-Analysis. Lancet 373, 746-758
21. Cipriani A, Hawton K, Stockton S, Geddes JR (2013). Lithium in the prevention of suicide in mood disorDers: updated systematic review and meta-Analysis. British Medical Journal 346, f3646
22. Dias S, Welton NJ, Caldwell DM, Ades AE (2010). Checking consistency in mixed treatment comparison meta-Analysis. Statistics in Medicine 29, 932-944
23. Drevets WC, Price JL, Simpson JR Jr., Todd RD, Reich T, Vannier M, Raichle ME (1997). Subgenual prefrontal cortex abnormalities in mood disorDers. Nature 386, 824-827
24. Eckermann S, Coory M, Willan AR (2009). Indirect comparison: relative risk fallacies and odds solution. Journal of Clinical Epidemiology 62, 1031-1036
25. Endicott J, Spitzer RL (1978). Diagnostic interview: the schedule for affective disorDers and schizophrenia. Achieves of General Psychiatry 35, 837-844
26. Freeman TW, Clothier JL, Pazzaglia P, Lesem MD, Swann AC (1992). Double-blind comparison of valproate and lithium in the treatment of acute mania. American Journal of Psychiatry 149, 108-111
27. Gardner DM, Murphy AL, ODonnell H, Centorrino F, Baldessarini RJ (2010). International consensus study of antipsychotic dosing. American Journal of Psychiatry 167, 686-693
28. Garza-Trevio ES, Overall JE, Hollister LE (1992). Verapamil vs. lithium in acute mania. American Journal of Psychiatry 149, 121-122
29. Glenny AM, Altman DG, Song F, Sakarovitch C, Deeks JJ, DAmico R, Bradburn M, Eastwood AJ (2005). Indirect comparisons of competing interventions. Health Technology Assessment 9, 1-134
30. Goldsmith DR, Wagstaff AJ, Ibbotson T, Perry CM (2003). Lamotrigine: review of its use in bipolar disorDer. Study ID Number: SCAA2008. Drugs 63, 2029-2050
31. Goodwin RK, Jamison KR (2007). Manic-Depressive Illness, 2nd edn. Oxford University Press: New York, NY
32. Grande I, Bernardo M, Bobes J, Saiz-Ruiz J, Alamo C, Vieta E (2014). Antipsychotic switching in bipolar disorDers: a systematic review. International Journal of Neuropsychopharmacology 17, 497-507
33. Janicak PG, Sharma RP, Pandey G, Davis JM (1998). Verapamil for the treatment of acute mania: double-blind, placebo-controlled trial. American Journal of Psychiatry 155, 972-973
34. Jonas D, Wilkins T, Bangdiwala S, Bann C, Morgan L, Thaler K, Amick H, Gartlehner G (2013). Findings of Bayesian Mixed Treatment Comparison Meta-Analyses, Comparison and Exploration using Real-World Trial data and Simulation. Agency for Healthcare Research and Quality (US), Methods Research Report No. 13-EHC039-EF
35. Kakkar AK, Rehan HS, Unni KES, Gupta NK, Chopra D, Kataria D (2009). Comparative efficacy and safety of oxcarbazepine versus divalproex sodium in the treatment of acute mania: pilot study. European Psychiatry 24, 178-182
36. Knesevich M, Papadakis K, Bose A, Andor G, Laszlovszky I (2009). The efficacy and tolerability of cariprazine in acute mania associated with bipolar I disorDer: a phase II trial. ClinicalTrials.gov: NCT00488618. European Neuropsychopharmacology 19 (Suppl. 3), S469
37. Kriston L, Yildiz A (in press). Traditional and novel research synthesis approaches to support eviDence-based treatment decisions In Bipolar Book: History, Neurobiology, and Treatment (ed. A. Yildiz, C. Nemeroff and P. Ruiz). Oxford University Press: New York
38. Laursen TM (2011). Life expectancy among persons with schizophrenia or bipolar affective disorDer. Schizophrenia Research 131, 101-104
39. Leboyer M, Soreca I, Scott J, Frye M, Henry C, Tamouza R, Kupfer DJ (2012). Can bipolar disorDer be viewed as a multi-system inflammatory disease? Journal of Affective DisorDers 141, 1-10
40. Lerer B, Moore N, Meyendorff E, Cho SR, Gershon S (1987). Carbamazepine vs. lithium in mania: double-blind study. Journal of Clinical Psychiatry 48, 89-93
41. Leucht S, Cipriani A, Spineli L, Mavridis D, Orey D, Richter F, Samara M, Barbui C, Engel RR, Geddes JR, Kissling W, Stapf MP, Lssig B, Salanti G, Davis JM (2013). Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-Analysis. Lancet 382, 951-962
42. Li H, Ma C, Wang G, Zhu X, Peng M, Gu N (2008). Response and remission rates in Chinese patients with bipolar mania treated for 4 weeks with either quetiapine or lithium: randomized and double-blind study. ClinicalTrials.gov: NCT00448578. Current Medical Research and Opinion 24, 1-10
43. Lu G, Ades AE (2004). Combination of direct and indirect eviDence in mixed treatment comparisons. Statistics in Medicine 23, 3105-3124
44. Machado-Vieira R, Manji HK, Zarate Jr. CA (2009). The role of lithium in the treatment of bipolar disorDer: convergent eviDence for neurotrophic effects as a unifying hypothesis. Bipolar DisorDers 11 (Suppl. 2), 92-109
45. Mauri D, Polyzos NP, Salanti G, Pavlidis N, Ioannidis JP (2008). Multiple-treatments meta-Analysis of chemotherapy and targeted therapies in adVanced breast cancer. Journal of the National Cancer Institute 100, 1780-1791
46. McElroy SL, Martens BE, Creech RS, Welge JA, Jefferson L, Guerdjikova AI, Keck PE Jr. (2010a). Randomized, double-blind, placebo-controlled study of divalproex extended release loading monotherapy in ambulatory bipolar spectrum disorDer patients with moDerate-to-severe hypomania or mild mania. Journal of Clinical Psychiatry 71, 557-565
47. McElroy SL, Martens BE, Winstanley EL, Creech R, Malhotra S, Keck Jr. PE (2010b). Placebo-controlled study of quetiapine monotherapy in ambulatory bipolar spectrum disorDer with moDerate-to-severe hypomania or mild mania. Journal of Affective DisorDers 124, 157-163
48. Merikangas KR, Akiskal HS, Angst J, Greenberg PE, Hirschfeld RM, Petukhova M, Kessler RC (2007). Lifetime and 12-month prevalence of bipolar spectrum disorDer in the national comorbidity survey replication. Achieves of General Psychiatry 64, 543-552
49. Moreno SG, Sutton AJ, Ades AE, Stanley TD, Abrams KR, Peters JL, Cooper NJ (2009). Assessment of regression-based methods to adjust for publication bias through a comprehensive simulation study. BMC Medical Research Methodology 9, 2
50. Mosolov SN, Kostiukova EG, Kapiletti SG, Belenkaia DV, Shafarenko AA, Fedotov DD (2009). Open randomized comparative twelve-week study of lithium and valproate in manic episode [in Russian]. Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova 109, 47-52
51. Mizuno Y, Suzuki T, Nakagawa A, Yoshida K, Mimura M, Fleischhacker WW, Uchida H (2014). Pharmacological strategies to counteract antipsychotic-induced weight gain and metabolic adverse effects in schizophrenia: systematic review and meta-Analysis. Schizophrenia Bulletin. Published online: 17 March 2014. PMID: 24636967
52. Novartis Clinical Trial Results Database, (2007). Randomized, double-blind, placebo-controlled multicenter study to evaluate efficacy and tolerability of licabazepine, 1000-2000 mg/d in the treatment of manic episodes of bipolar I disorDer over 3 weeks. Study ID, Number: CLIC477D2301. ClinicalTrials.gov: NCT00099229 (data on file)
53. Ortega Soto HA (1993). Carbamazepine vs haloperidol in treatment of manic episodes: controlled clinical trial. (Spanish) Salud Mental 16, 44-50
54. Osby U, Brandt L, Correia N, Ekbom A, Sparn P. (2001), Excess mortality in bipolar and unipolar disorDer in SweDen, Achieves of General Psychiatry. 58. 844-850
55. Pfizer Clinical Trial Results Database (2008). Multicenter, randomized, double-blind, parallel group study, comparing the efficacy and tolerability of ziprasidone (Zeldox, Geodon) vs olanzapine (Zyprexa) in the treatment and maintenance of response in patients with acute mania. Study ID Number: A1281147. ClinicalTrials.gov: NCT00329108 (data on file
56. Salanti G, Ades AE, Ioannidis JP (2011). Graphical methods and numerical summaries for presenting results from multiple-treatment meta-Analysis: an overview and tutorial. Journal of Clinical Epidemiology 64, 163-171
57. Salanti G, Higgins JPT, Ades AE, Ioannidis JPA (2008). Evaluation of networks of randomized trials. Statistical Methods in Medical Research 17, 279-301
58. Salanti G, Marinho V, Higgins JPT (2009). Case study of multiple-treatments meta-Analysis demonstrates that covariates should be consiDered. Journal of Clinical Epidemiology 62, 857-864
59. Shafti SS (2010). Olanzapine vs. lithium in management of acute mania. Journal of Affective DisorDers 122, 273-276
60. Shafti SS, Shahveisi B (2008). Comparison between lithium and valproate in the treatment of acute mania. Journal of Clinical Psychopharmacology 28, 718-720
61. Spiegelhalter DJ, Best NG, Carlin BP, Van Der Linde A (2002). Bayesian measures of model complexity and fit. Journal of the Royal Statistical Society 64, 583-639
62. Spitzer RL, Endicott J, Robins E (1978). Research diagnostic criteria: rationale and reliability. Archives of General Psychiatry 35, 773-782
63. Tondo L, Lepri B, Baldessarini RJ (2007). Risks of suicidal ideation, attempts and suicides among 2826 men and women with types I and II bipolar, and recurrent major depressive disorDers. Acta Psychiatrica Scandinavica 116, 419-428
64. Vasudev K, Goswami U, Kohli K (2000). Carbamazepine and valproate monotherapy: feasibility, relative safety and efficacy, and therapeutic drug monitoring in manic disorDer. Psychopharmacology 150, 15-23
65. Vernon AC, Natesan S, Crum WR, Cooper JD, Modo M, Williams SC, Kapur S (2012). Contrasting effects of haloperidol and lithium on roDent brain structure: magnetic resonance imaging study with postmortem confirmation. Biological Psychiatry 71, 855-863
66. Vieta E, Cruz N (2012). Head to head comparisons as an alternative to placebo-controlled trials. European Neuropsychopharmacology 22, 800-803
67. Vieta E, Langosch JM, Figueira ML, Souery D, Blasco-Colmenares E, Medina E, Moreno-Manzanaro M, Gonzalez MA, Bellivier F (2013). Clinical management and burDen of bipolar disorDer: results from a multinational longitudinal study (WAVE-bd). International Journal of Neuropsychopharmacology 16, 1719-1732
68. Woo G, Tomlinson G, Nishikawa Y, Kowgier M, Sherman M, Wong DK, Pham B, Ungar WJ, Einarson TR, Heathcote EJ, Krahn M (2010). Tenofovir and entecavir are the most effective antiviral agents for chronic hepatitis B: systematic review and Bayesian meta-Analysis. Gastroenterology 139, 1218-1229
69. Yildiz A, Guleryuz S, Ankerst DP, Ongür D, Renshaw PF (2008). Protein kinase C inhibition in the treatment of mania: double-blind, placebo-controlled trial of tamoxifen. Archives of General Psychiatry 65, 255-263
70. Yildiz A, Undurraga J, Vieta E, Popovic D, WooDerson S, Young A (in press a). Strategies for improving randomized trial eviDence in treatment of bipolar disorDer. In Bipolar Book: History, Neurobiology, and Treatment (ed. A. Yildiz, C. Nemeroff and P. Ruiz). Oxford University Press: New York
71. Yildiz A, Vieta E, Correll CU, Nikodem M, Baldessarini RJ (in press b). Critical issues on use of network meta-Analysis in psychiatry. Harvard Review of Psychiatry
72. Yildiz A, Vieta E, Leucht S, Baldessarini RJ (2011a). Efficacy of antimanic treatments: meta-Analysis of randomized controlled trials. Neuropsychopharmacology 36, 375-389
73. Yildiz A, Vieta E, Tohen M, Baldessarini RJ (2011b). Factors modifying drug and placebo responses in randomized trials for acute mania. International Journal of Neuropsychopharmacology 14, 863-875
74. Young RC, Biggs JT, Ziegler VE, Meyer DA (1978). Rating scale for mania: reliability, validity and sensitivity. British Journal of Psychiatry 133, 429-435
75. Zarate CA Jr., Singh JB, Carlson PJ, Quiroz J, Jolkovsky L, Luckenbaugh DA, Manji HK (2007). Efficacy of a protein kinase C inhibitor (tamoxifen) in the treatment of acute mania: a pilot study. Bipolar DisorDers 9, 561-570